发明公开
- 专利标题: HETERO COMPOUND
- 专利标题(中): 恶二唑化合物S1P1-Agonisten
-
申请号: EP07740850.8申请日: 2007-04-02
-
公开(公告)号: EP2003132A1公开(公告)日: 2008-12-17
- 发明人: HARADA, Hironori , HATTORI, Kazuyuki , FUJITA, Kazuya , MORITA, Masataka , IMADA, Sunao , ABE, Yoshito , ITANI, Hiromichi , MOROKATA, Tatsuaki , TSUTSUMI, Hideo
- 申请人: Astellas Pharma Inc.
- 申请人地址: 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411 JP
- 专利权人: Astellas Pharma Inc.
- 当前专利权人: Astellas Pharma Inc.
- 当前专利权人地址: 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411 JP
- 代理机构: HOFFMANN EITLE
- 优先权: JP2006102544 20060403; JP2006276693 20061010; JP2006279227 20061012
- 国际公布: WO2007116866 20071018
- 主分类号: C07D413/04
- IPC分类号: C07D413/04 ; A61K31/4245 ; A61K31/4353 ; A61K31/4709 ; A61P37/02 ; A61P37/06 ; A61P43/00 ; C07D417/04 ; C07D471/04
摘要:
[Problems]
To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P 1 agonist activity.
[Means for solving]
Since the compound of the invention has an S1P 1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.
To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P 1 agonist activity.
[Means for solving]
Since the compound of the invention has an S1P 1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.
公开/授权文献
- EP2003132B1 Oxadiazole derivatives as S1P1 agonists 公开/授权日:2014-03-05
信息查询